Phil Smith Neuroscience Institute selected for HEALEY ALS Platform Trial

The Phil Smith Neuroscience Institute at Holy Cross Hospital has been selected for the HEALEY ALS Platform Trial by the Sean M. Healey & AMG Center at Massachusetts General Hospital.

The Sean M. Healey & AMG Center, in collaboration with the Northeast ALS Consortium (NEALS), is launching the first platform trial for amyotrophic lateral sclerosis (ALS). The goals of this groundbreaking project are to greatly accelerate the timelines towards effective ALS treatments and provide greater trial access for all those affected by this disease.

“Our patients have access to first class research and leading-edge clinical trials and treatments at the Phil Smith Neuroscience Institute through our expanded relationship with Massachusetts General Hospital,” said Paul Papagni, JD, executive director of research at Holy Cross Hospital. “The HEALEY ALS Platform Trial will begin in early 2020.”

The HEALEY ALS Platform Trial is a collaborative effort and enrollment in the trial will be available at several sites across the U.S. to bring the trial close to people who want to participate. All sites are part of the NEALS Consortium.

Holy Cross Hospital opened the Phil Smith Neuroscience Institute and Phil Smith ALS and Movement Disorders Clinic in 2018. More than 15 neuro physician specialists at the Phil Smith Neuroscience Institute provide comprehensive neurological and neurosurgical care for a variety of conditions.

The Institute meets the needs of patients living with these diseases and conditions, providing support and enhancing access to services and treatment. It is the only specialized care for ALS patients in Broward and Palm Beach counties.

For more information about the HEALEY ALS Platform Trial, call 954-229-8553 or email paul.papagni@holy-cross.com.